 CHARLOTTESVILLE, VA ACCESSWIRE January 11, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced receipt of a Notice of Allowance for its third U.S. patent relating to the use of AD04 for the treatment of opioid use disorder OUD. The patent covers the use of the Companys lead product, AD04, as a treatment of Opioid Use Disorder in patients with a specific genetic biomarker in the serotonin transporter gene. 